Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. Its tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology. The company was founded by Jennifer A. Doudna, Rachel E. Haurwitz, Martin Jinek and James Berger on October 28, 2011 and is headquartered in Berkeley, CA.
相关临床试验
5
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2011
Enrolling By Invitation
1
20.0%
招募中
2
40.0%
终止
1
20.0%
撤回
1
20.0%
暂无批准数据
- Olema Oncology has appointed Jason O'Byrne, MBA, as Chief Financial Officer as the company approaches pivotal data from its OPERA-01 study and a potential first commercial launch. - O'Byrne joins from Vir Biotechnology, where he served as Executive Vice President and CFO, and previously held CFO roles at Caribou Biosciences and Audentes Therapeutics. - His background spans corporate strategy, capital markets, business development, and financial management, including leadership of Caribou's IPO and the $3 billion Astellas acquisition of Audentes. - Olema highlighted its strong balance sheet as it advances palazestrant (OP-1250) and OP-3136 toward multiple upcoming milestones in breast cancer and beyond.
- The global gene editing therapeutics market is projected to grow at a compound annual growth rate of 12.5%, fueled by expanding clinical applications and rising disease burden. - CRISPR-based technologies dominate the market due to their efficiency and cost-effectiveness, while oncology represents the largest therapeutic application segment. - High development costs, regulatory complexity, and off-target safety concerns remain significant barriers to broader adoption and commercialization. - Key players including CRISPR Therapeutics, Intellia Therapeutics, Editas Medicine, and Beam Therapeutics are driving innovation through partnerships and investments in next-generation editing platforms.
- Caribou Biosciences released updated clinical data for CB-010, its lead allogeneic CAR-T cell therapy targeting CD19 for relapsed or refractory B-cell non-Hodgkin lymphoma, in May 2026. - The company's ANTLER phase 1 trial data highlighted response durability and safety details that could shape expectations for the gene-editing specialist's pipeline. - CB-010 utilizes Caribou's proprietary CRISPR hybrid RNA-DNA (chRDNA) platform designed to improve editing specificity and create off-the-shelf therapies that avoid immune rejection. - The company is also advancing CB-011, a BCMA-directed allogeneic CAR-T candidate for multiple myeloma, with early anti-tumor activity reported in the CaMMouflage phase 1 trial.
- Watchmaker Genomics secured a non-exclusive license from Caribou Biosciences for foundational CRISPR-Cas9 intellectual property to revolutionize next-generation sequencing library preparation workflows. - The company is applying CRISPR-Cas9 technology as a programmable binding tool for library normalization, addressing a persistent bottleneck in NGS workflows that has become problematic as sequencing throughput scales. - This novel approach uses adapter-specific guides to bind sequencing-ready libraries in a controlled manner, enabling standardization without extensive quantification while preserving library integrity and complexity. - The technology will be integrated into a complete PCR-free whole genome sequencing solution targeting large-scale population studies, newborn screening, and rare disease applications.
- Caribou Biosciences will host a webcast on November 3, 2025, to present new data from the ANTLER Phase 1 trial of vispa-cel in relapsed/refractory B-cell non-Hodgkin lymphoma. - The company will report first clinical data from the CaMMouflage Phase 1 trial evaluating CB-011, an allogeneic anti-BCMA CAR-T therapy, in patients with relapsed/refractory multiple myeloma. - Caribou will outline its anticipated pivotal Phase 3 trial design for vispa-cel and next steps for CB-011's continued clinical development. - Both therapies represent innovative CRISPR-edited allogeneic CAR-T approaches with unique genome-editing strategies designed to enhance therapeutic activity and reduce immune rejection.
- Caribou Biosciences received FDA clearance for its Investigational New Drug (IND) application, marking a critical regulatory milestone for the company's cell therapy development program. - The stock surged 9.38% in a single trading session and gained 40% over five consecutive days, reaching its highest level since January 2025. - Cambridge Investment Research Advisors Inc. acquired a new $559,000 stake in the company, reflecting growing institutional confidence in Caribou's innovative research and development efforts. - The company has regained compliance with Nasdaq listing requirements, providing a stable foundation for future growth and enhanced market attractiveness to investors.
- The CAR-T cell therapy industry has raised over $141.2 billion through various financing mechanisms, with estimates suggesting total industry funding could reach $281.7 billion when including undisclosed deals. - More than 170 companies worldwide are developing CAR-T products with 1,944 therapies in development, while 13 CAR-T cell therapies have received regulatory approval globally since 2017. - Despite a slowdown in IPOs and M&A activity in 2024, venture capital funding remains strong with 89 CAR-T companies securing $7.7 billion since 2014, supporting advancement in both blood cancer and solid tumor applications.
- The global lupus nephritis market is projected to grow significantly by 2034, with the United States accounting for over 80% of the current $1.12 billion market share across major regions. - Several innovative therapies are advancing through clinical trials, including CAR-T cell treatments from companies like Allogene Therapeutics, Adicet Bio, and Caribou Biosciences, which received FDA Fast Track designations. - Key pharmaceutical players including Aurinia Pharmaceuticals, AstraZeneca, and Roche are developing treatments such as voclosporin, anifrolumab, and obinutuzumab to address the significant unmet needs in lupus nephritis management.
• Caribou Biosciences is cutting 32% of its workforce and discontinuing its experimental lupus treatment to concentrate resources on two promising off-the-shelf CAR-T therapies for cancer. • The CRISPR gene editing company is delaying planned clinical trial readouts until the second half of 2023 to gather more robust data on its CB-010 and CB-011 therapies for lymphoma and multiple myeloma. • The restructuring will extend Caribou's financial runway from mid-2026 to late 2027, as the company makes an all-or-nothing bet on proving its cell therapies can match the efficacy of personalized CAR-T treatments.
- CRISPR Medicine News tracks approximately 250 clinical trials involving gene-editing therapeutic candidates as of February 2025, with more than 150 trials currently active across diverse therapeutic areas. - CASGEVY became the first approved CRISPR-based therapy in 2023, receiving regulatory clearance in multiple regions for treating sickle cell disease and beta thalassemia through foetal haemoglobin induction. - Gene editing for blood disorders continues to lead the clinical landscape, with the majority of Phase 3 trials targeting sickle cell disease and beta thalassemia, while Phase 3 trials are also underway in hereditary amyloidosis and immunodeficiencies. - Clinical applications now span 15+ therapeutic areas including blood cancers, viral diseases, metabolic disorders, autoimmune diseases, inherited eye diseases, cardiovascular disease, and neurological conditions.
